Virologist Combats Stage 3 Breast Cancer Using Viruses Cultured in Her Lab

In 2020, Dr. Beata Halassy, a 49-year-old virologist affiliated with the University of Zagreb, received the frightening news that her stage 3 breast cancer had returned after a previous mastectomy. Rather than submitting to another exhausting round of chemotherapy, she chose a bold path: applying her expertise in virology to develop a personalized treatment for her cancer.

Her method centered on oncolytic virotherapy, an innovative cancer treatment that employs viruses to selectively infect and destroy malignant cells while activating the body’s immune defenses. While typically reserved for metastatic cancers in clinical experiments, Dr. Halassy’s case represents a novel use of this approach to treat an earlier phase of breast cancer.

Relying on her scientific background, Dr. Halassy identified two viruses apt to her tumor’s cell type:

Add Cosmo Herald as a Preferred Source

Measles virus
Vesicular stomatitis virus (VSV), resembling influenza virus

Both viruses were known to target the specific cancer cells in her tumor, highlighting the promise of tailoring treatments to individual patients, much like breakthrough blood tests that reveal cancer before symptoms emerge. Such personalized interventions could revolutionize therapeutic outcomes.

Details of Treatment and Impressive Outcomes

Over the span of two months, she received the viral agents directly injected into the tumor by a trusted colleague, while oncologists vigilantly monitored her condition to ensure safety and readiness to initiate conventional therapy if needed. The effects were remarkable:

Following surgical removal, examination revealed that the tumor was densely populated by lymphocytes, revealing that the virotherapy had effectively stimulated her immune system to target both the viruses and malignant cells. To further guard against relapse, she subsequently received standard anticancer drug treatment.

This successful case echoes other novel medical advances, such as methods that remove the chronic dependence on insulin for type 2 diabetes, showcasing how breakthrough approaches can redefine management of persistent diseases.

Scientific Ethics and Controversy

Dr. Halassy’s transition from researcher to patient self-experimenter has stirred significant controversy within the scientific world. Despite her promising findings, she encountered repeated refusals—over a dozen—from peer-reviewed journals unwilling to publish her work. This resistance is linked not to the practice of self-testing, but to concerns about reception and consequences of distributing these results.

Jacob Sherkow, an expert in health law and ethics, outlines the ethical challenges facing the community:

Apprehension that such reports may discourage adherence to established treatments
Worries that others might attempt hazardous self-experiments
The responsibility to balance innovation with patient protection

Conversely, virotherapy specialist Dr. Stephen Russell highlights a unique aspect of this case: the use of viruses propagated personally in Dr. Halassy’s lab. This innovative step pushes the boundaries of custom-designed treatments and patient-led interventions beyond current norms.

By joining a tradition of scientists who have tested therapies on themselves—often at ethical risk—Dr. Halassy’s experience has contributed valuable insights. Now four years cancer-free, she remains committed to sharing her story and encouraging further research into oncolytic virotherapy’s potential for treating cancers across diverse stages.